The medical community is slow to adopt advanced preventative tools like genomic sequencing. Change will not come from the top down. Instead, educated and savvy patients demanding these tests from their doctors will be the primary drivers of the necessary revolution in personalized healthcare.

Unlike US industrial CEOs, who are often finance-focused and risk-averse, leaders in the UAE and Saudi Arabia see technological transformation as vital for national survival. This existential pressure drives them to make bigger, bolder bets on AI and robotics to future-proof their economies.

UAE Minister Omar Al Olama argues that AI can level the playing field for smaller countries. By dramatically boosting productivity and intelligence, nations with smaller populations can achieve an impact and economic output disproportionate to their size, earning them a seat at the global table.

Long before the current hype, a 2005 AI project used electronic medical records and genomic data to find children with an ultra-rare disease who would have otherwise died before age 10. This highlights AI's long-standing, life-saving impact beyond recent commercial applications.

In a meeting with political figures, gene editing pioneer David Liu set an audacious public goal of achieving 1,000 bespoke "N-of-1" cures, similar to the famous Baby KJ case, by 2030. This marks a shift towards public accountability and sets a quantitative benchmark for the entire precision medicine field.

The UAE aims to become a third AI power by serving the 4 billion people between Milan and Singapore. Its strategy hinges on acting as a "trustworthy third party," leveraging strong corporate data protection laws—akin to diplomatic immunity—to build trust and attract global partners like OpenAI.

Thriving life sciences ecosystems in Ireland, the UK, and Massachusetts did not grow by accident. Their success is the result of deliberate, long-term government strategies, including tax incentives, shared R&D infrastructure like the UK's 'Catapult' network, and fostering deep connections between technology, hospitals, and capital.

Faced with a US market fixated on AI, CellSci is seeking approval and funding in Saudi Arabia. The nation's "Vision 2030" plan to become a global biotech hub creates opportunities for innovative companies to gain access to capital and a more favorable regulatory environment.

China is poised to become the next leader in biotechnology due to a combination of structural advantages. Their regulatory environment is moving faster, they have a deep talent pool, and they can conduct clinical trials at a greater speed and volume than the U.S., giving them a significant edge.